Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK

Meier, Christoph R.; Jick, Hershel; Meier, C R; Jick, H
July 1997
Thorax;Jul1997, Vol. 52 Issue 7, p612
Academic Journal
journal article
No abstract available.


Related Articles

  • Comparison of Two Methods of Administering Bronchodilator Aerosol to Asthmatic Patients. Choo-Kang, Y.F.J.; Grant, I.W.B. // British Medical Journal;4/19/75, Vol. 2 Issue 5963, p119 

    Compares the effects of bronchodilator drugs in patients with chronic asthma. Result after the administration by intermittent positive-pressure ventilation (IPPV); Superiority of IPPV; Sympathomimetic bronchodilator implicated in increased death rate from asthma.

  • Inhaled corticosteroids as combination therapy with β-adrenergic agonists in airways disease: present and future. Kian Fan Chung; Caramori, Gaetano; Adcock, Ian M. // European Journal of Clinical Pharmacology;Sep2009, Vol. 65 Issue 9, p853 

    Inhaled corticosteroid (ICS) therapy in combination with long-acting β-adrenergic agonists represents the most important treatment for chronic airways diseases such as asthma and chronic obstructive pulmonary disease (COPD). ICS therapy forms the basis for treatment of asthma of all...

  • Are asthma drugs a cure that kills? Bown, William // New Scientist;4/6/91, Vol. 130 Issue 1763, p17 

    Ponders whether the drugs used to treat asthma are implicated in the increase in death rates from asthma. Beta-2 agonists and how they work; Statistics on death rates from asthma in Britain; Problems in finding the reasons for the increase in death rates; Changes in Western lifestyles and the...

  • United States : FDA approval for BOEHRINGER drug.  // TendersInfo News;8/23/2014, p1 

    The article reports that U.S. Food and Drug Administration (FDA) has announced approval to the Ridgefield-based pharmaceutical firm, Boehringer Ingelheim drug for use by chronic obstructive pulmonary disease patients with various safety warnings, including the risk of asthma-related death.

  • Salmeterol investigation halted. Pinkowish, Mary Desmond // Patient Care;Mar2003, Vol. 37 Issue 3, p13 

    Reports on the suspension of a safety study on salmeterol due to a trend toward an increased risk of asthma deaths and fatal asthma attacks in the U.S. Objective of the study; Types of patients who demonstrated risk of fatal asthma; Recommendations from the U.S. Food and Drug Administration on...

  • Pulmonary Arterial Hypertension in Adults: Novel Drugs and Catheter Ablation Techniques Show Promise? Systematic Review on Pharmacotherapy and Interventional Strategies. Rosanio, Salvatore; Pelliccia, Francesco; Gaudio, Carlo; Greco, Cesare; Keylani, Abdul M.; D'Agostino, Darrin C. // BioMed Research International;2014, Vol. 2014, p1 

    This systematic review aims to provide an update on pharmacological and interventional strategies for the treatment of pulmonary arterial hypertension in adults. Currently US Food and Drug Administration approved drugs including prostanoids, endothelinreceptor antagonists, phosphodiesterase...

  • FDA curbs LABA use for asthma.  // Drug Topics;Mar2010, Vol. 154 Issue 3, p12 

    The article reports on the limitations recommended by the U.S. Food and Drug Administration (FDA) in using long-acting beta2-adrenergic agonists (LABAs) in the treatment of asthma. It mentions that the decision was made due to the increasing death rates connected with LABA use. It adds that the...

  • Glaxo urges proper use of salmeterol.  // Modern Medicine;Jan95, Vol. 63 Issue 1, p28 

    Reveals the labeling changes that the drug company Glaxo is contemplating for salmeterol xinafoate (Serevent) to educate physicians and patients on the proper use of the bronchodilator for managing asthma. Inaccuracy of reports linking Serevent to deaths of asthma patients; Approved use of the...

  • Türkiye'de Astım Tedavisinde Geleneksel Olarak Kullanılan Bitkiler. MELİKOĞLU, Gülay; KURTOĞLU, Sezin; KÜLTÜR, Şükran // Marmara Pharmaceutical Journal;2015, Vol. 19 Issue 1, p1 

    Asthma is the chronic inflammatory disease of respiratory system. Mainly personal and environmental risk factors play role in its development. Personal factors are genetic, obesity, gender, and the environmental factors are, allergens, infections, vocational reasons, smoking, air pollution and...

  • Omalizumab for Allergic Asthma. Elliott, William T. // Primary Care Reports;Sep2009 Supplement, p2 

    The article reports that the Food and Drug Administration (FDA) in the U.S. is assessing the safety of omalizumab, Xolair®, used against allergic asthma. The FDA found from the ongoing study of the drug that there was an increase incidents of various diseases in patients, including ischemic...


Read the Article


Sign out of this library

Other Topics